Our proprietary platform- microfluidic chip, antibody, and imaging software- has enabled us to be the only company to overcome the “intractable” challenge of detecting rare CTCs in pre-cancer and early stage patients, when cancer can be successfully treated.
Technology limitations have restricted other CTC and ctDNA technologies to advanced cancers when it is unfortunately too late to impact outcome for most patients.